Morgan Stanley Instil Bio, Inc. Transaction History

Morgan Stanley

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$0.4 - $0.63 $19,330 - $30,446	-48,327 Reduced 59.08%	33,476 $14,000
Q2 2023 Aug 14, 2023	SELL	$0.51 - $0.67 $5,768 - $7,578	-11,311 Reduced 12.15%	81,803 $44,000
Q1 2023 May 15, 2023	BUY	$0.6 - $0.91 $5,440 - $8,251	9,068 Added 10.79%	93,114 $61,000
Q4 2022 Feb 14, 2023	SELL	$0.48 - $5.33 $68,689 - $762,738	-143,103 Reduced 63.0%	84,046 $52,000
Q3 2022 Nov 14, 2022	BUY	$4.65 - $7.37 $406,754 - $644,683	87,474 Added 62.63%	227,149 $1.1 Million
Q2 2022 Oct 27, 2022	BUY	$4.21 - $11.15 $454,709 - $1.2 Million	108,007 Added 341.06%	139,675 $645,000
Q2 2022 Aug 15, 2022	BUY	$4.21 - $11.15 $454,709 - $1.2 Million	108,007 Added 341.06%	139,675 $645,000
Q1 2022 Oct 27, 2022	SELL	$8.48 - $18.1 $915,899 - $1.95 Million	-108,007 Reduced 77.33%	31,668 $340,000
Q1 2022 May 13, 2022	SELL	$8.48 - $18.1 $106,983 - $228,349	-12,616 Reduced 28.49%	31,668 $340,000
Q4 2021 Feb 14, 2022	BUY	$15.37 - $22.5 $568,044 - $831,555	36,958 Added 504.48%	44,284 $757,000
Q3 2021 Nov 15, 2021	BUY	$15.05 - $23.28 $110,256 - $170,549	7,326 New	7,326 $131,000

1.9M

Ticker TIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,694,000
Market Cap $3.23B
Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small ce...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.